Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cefoxitin Sodium

FDA-approved product (injectable, injection), marketed as Cefoxitin, Cefoxitin And Dextrose In Duplex Container, Cefoxitin In Plastic Container and 4 more.

Registered studies
29
Lab records
132
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Cefoxitin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Infection
  • Pneumonia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Second-generation cephalosporins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DC01

Repurposing investigation

Cefoxitin Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA65.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli65.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae18.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis53.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

29registered studies name this medicine, for any condition. See them below.

Experimental

  • MRSA: measured active in 5 of 10 lab records
  • E. coli: measured active in 1 of 1 lab record
  • K. pneumoniae: measured active in 32 of 121 lab records
Open Cefoxitin Sodium in ChEMBL Registered studies below
Show the 132 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cefoxitin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

    NCT07485010 · start 2027-04

    Registered record
    Registry ID
    NCT07485010
    Conditions
    Mycobacterium Abscessus Pulmonary Disease; Mycobacterium Abscessus Infection; Non-Tuberculous Mycobacterial (NTM) Infections; Non-Tuberculous Mycobacteria Pulmonary Disease
    Interventions
    Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours); Ceftriaxone for Injection; Amoxicillin; Azithromcyin; clarithromycin; Clofazimine; Ethambutol; Amikacin Injection; tigecycline; Imipenem + Cilastatin; Cefoxitin; Amikacin (Inhalation); linezolid; Trimethoprim / Sulfamethoxazole; Doxycycline; moxifloxacin; bedaquiline; Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2027-04
    Completion
    2031-07
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Abscessus Pulmonary Disease; Mycobacterium Abscessus Infection; Non-Tuberculous Mycobacterial (NTM) Infections; Non-Tuberculous Mycobacteria Pulmonary Disease
    InterventionSulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours); Ceftriaxone for Injection; Amoxicillin; Azithromcyin +14 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Duration of Perioperative Antibiotics in Pancreatoduodenectomy

    NCT07043855 · start 2026-05-11

    Registered record
    Registry ID
    NCT07043855
    Conditions
    Pancreatoduodenectomy; PPPD; Infectious Complications
    Interventions
    single dose preoperative antibiotic; Prolonged perioperative antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Enrolling by invitation
    Start
    2026-05-11
    Completion
    2028-12
    Enrolment
    558

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatoduodenectomy; PPPD; Infectious Complications
    Interventionsingle dose preoperative antibiotic; Prolonged perioperative antibiotics
    PhaseNot applicable
    Registry statusEnrolling by invitation

  • Precision Antibiotic Dosing for Appendectomy

    NCT06860802 · start 2025-02-28

    Registered record
    Registry ID
    NCT06860802
    Conditions
    Appendicitis (Diagnosis)
    Interventions
    Cefoxitin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2025-02-28
    Completion
    2026-09-30
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAppendicitis (Diagnosis)
    InterventionCefoxitin
    PhasePhase 1
    Registry statusActive not recruiting

  • Intermittent Cefoxitin Administration Versus Loading Bolus Followed by Continuous Infusion for the Prevention of Surgical Site Infection in Colorectal Surgery

    NCT05755789 · start 2023-06-22

    Registered record
    Registry ID
    NCT05755789
    Conditions
    Antibiotic Prophylaxis; Colorectal Surgery
    Interventions
    Loading bolus of cefoxitin; Intermittent cefoxitin; Continuous infusion of placebo; Continuous infusion of cefoxitin; Intermittent placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2023-06-22
    Completion
    2025-06
    Enrolment
    2,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntibiotic Prophylaxis; Colorectal Surgery
    InterventionLoading bolus of cefoxitin; Intermittent cefoxitin; Continuous infusion of placebo; Continuous infusion of cefoxitin +1 more
    PhasePhase 3
    Registry statusUnknown

  • Studying the Distribution of Accessory Gene Regulator (Agr) Quorum Sensing System and the Prevalence of Linezolid and Mupirocin Resistance in Biofilm Producer/Non Producer Staphylococcus Aureus in Sohag University Hospitals

    NCT06291181 · start 2023-01-01

    Registered record
    Registry ID
    NCT06291181
    Conditions
    Staphylococcus Aureus
    Interventions
    antibiotic sensitivity test
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-01-01
    Completion
    2023-06-30
    Enrolment
    265

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus
    Interventionantibiotic sensitivity test
    PhaseNot applicable
    Registry statusCompleted

  • Vaginal Adventitia Reserved and Anatomical Implant Technique of Transvaginal Mesh Procedure for Pelvic Organ Prolapse

    NCT05707533 · start 2022-08-01

    Registered record
    Registry ID
    NCT05707533
    Conditions
    Pelvic Organ Prolapse
    Interventions
    TVM using the Vaginal Adventitia Reserved and Anatomical Implant Technique
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-08-01
    Completion
    2022-11-30
    Enrolment
    589

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPelvic Organ Prolapse
    InterventionTVM using the Vaginal Adventitia Reserved and Anatomical Implant Technique
    PhaseNot recorded
    Registry statusCompleted

  • The Expected Advantage of Administering Prophylactic Antibiotics Using Target- Concentration Controlled Infusion

    NCT05253339 · start 2022-04-04

    Registered record
    Registry ID
    NCT05253339
    Conditions
    Anti-bacterial Agents; Pharmacokinetics; General Surgery
    Interventions
    target-controlled infusion (one of the administration methods); Standard administration method
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-04-04
    Completion
    2025-08-28
    Enrolment
    2,494

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnti-bacterial Agents; Pharmacokinetics; General Surgery
    Interventiontarget-controlled infusion (one of the administration methods); Standard administration method
    PhaseNot applicable
    Registry statusCompleted

  • A Multi-center Clinical Study of Drug Antibody and Precision Transfusion in China

    NCT05606302 · start 2021-10-01

    Registered record
    Registry ID
    NCT05606302
    Conditions
    Drug-specific Antibodies
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-10-01
    Completion
    2023-12
    Enrolment
    14,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug-specific Antibodies
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

    NCT04310930 · start 2020-03-02

    Registered record
    Registry ID
    NCT04310930
    Conditions
    Pulmonary Disease Due to Mycobacteria (Diagnosis)
    Interventions
    Amikacin; Tigecycline; Imipenem; Cefoxitin; Azithromycin; Clarithromycin; Clofazimine; Ethambutol; Amikacin; Linezolid; co-trimoxazole; Doxycycline; Moxifloxacin; Bedaquiline; Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2020-03-02
    Completion
    2030-06-30
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Disease Due to Mycobacteria (Diagnosis)
    InterventionAmikacin; Tigecycline; Imipenem; Cefoxitin +11 more
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Two-drug Antibiotic Prophylaxis in Scheduled Cesarean Deliveries

    NCT03960970 · start 2019-09-15

    Registered record
    Registry ID
    NCT03960970
    Conditions
    Endometritis; Cesarean Section; Infection; Wound Infection
    Interventions
    Azithromycin 500 mg; Mefoxin 2g
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2019-09-15
    Completion
    2020-11-30
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometritis; Cesarean Section; Infection; Wound Infection
    InterventionAzithromycin 500 mg; Mefoxin 2g
    PhasePhase 2
    Registry statusUnknown

  • Mechanical Bowel Preparation With or Without Oral Antibiotics for Colorectal Cancer Surgery

    NCT03563586 · start 2018-04-01

    Registered record
    Registry ID
    NCT03563586
    Conditions
    Antibiotic; Bowel Cancer; Colorectal Cancer; Surgical Site Infection
    Interventions
    Bowel Preparation plus antibiotics; Bowel Preparation
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2018-04-01
    Completion
    2021-06-01
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntibiotic; Bowel Cancer; Colorectal Cancer; Surgical Site Infection
    InterventionBowel Preparation plus antibiotics; Bowel Preparation
    PhaseNot applicable
    Registry statusUnknown

  • Evaluation of the Use of Cefoxitin in Combination in Continuous Parenteral Administration in the Treatment of Bone and Joint Infections

    NCT03848104 · start 2018-01-01

    Registered record
    Registry ID
    NCT03848104
    Conditions
    Antibiotic Reaction; Bone and Joint Infection
    Interventions
    bone and joint infection treated with cefoxitin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-01-01
    Completion
    2018-04-01
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntibiotic Reaction; Bone and Joint Infection
    Interventionbone and joint infection treated with cefoxitin
    PhaseNot recorded
    Registry statusCompleted

  • Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?

    NCT03269994 · start 2017-11-21

    Registered record
    Registry ID
    NCT03269994
    Conditions
    Pancreatic Cancer; Pancreas Cancer; Pancreatic Diseases
    Interventions
    Cefoxitin; Piperacillin-tazobactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-11-21
    Completion
    2025-01-28
    Enrolment
    967

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer; Pancreas Cancer; Pancreatic Diseases
    InterventionCefoxitin; Piperacillin-tazobactam
    PhasePhase 3
    Registry statusCompleted

  • Serum Concentration of CEFOxitin Used for Antibiotic Prophylaxis in Obese Patients Undergoing BARiatric Surgery

    NCT03306290 · start 2017-10-30

    Registered record
    Registry ID
    NCT03306290
    Conditions
    Obese; Antibiotic Prophylaxis; Bariatric Surgery Candidate
    Interventions
    Serum dosage of antibiotic prophylaxis CEFOXITIN
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-10-30
    Completion
    2018-08-09
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObese; Antibiotic Prophylaxis; Bariatric Surgery Candidate
    InterventionSerum dosage of antibiotic prophylaxis CEFOXITIN
    PhaseNot applicable
    Registry statusCompleted

  • Vancomycin and Cefoxitin During Pediatric Cardiopulmonary Bypass

    NCT02839486 · start 2017-10-01

    Registered record
    Registry ID
    NCT02839486
    Conditions
    Congenital Heart Disease
    Interventions
    vancomycin pharmacokinetics; cefoxitin pharmacokinetics
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-10-01
    Completion
    2019-07-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongenital Heart Disease
    Interventionvancomycin pharmacokinetics; cefoxitin pharmacokinetics
    PhaseNot recorded
    Registry statusCompleted